Servier has strengthened its neurology pipeline with the acquisition of a potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder, struck a deal with Kaerus Bioscience that could be worth $450m to the UK biotech for its oral small molecule KER-0193 should all the deal’s development and commercial milestones be reached.